Ir para o conteúdo principal

Imunon (NASDAQ: IMNN) — Perfil da empresa, notícias e dados financeiros

Logo de Imunon
IMNN Imunon
Imunon primary media
Perfil da empresa

Imunon

Imunon (NASDAQ:IMNN) specializes in pioneering the development of novel immunotherapies aimed at treating a variety of cancers. With a focus on leveraging cutting-edge scientific research, Imunon strives to unlock new pathways in immune modulation to combat malignancies. The company's robust project pipeline is centered on advancing treatments that harness the body's own immune system to fight cancer more effectively. Imunon is firmly committed to its mission of bringing groundbreaking cancer therapies from the lab to the clinic, thereby aiming to improve patient outcomes and enhance quality of life for those battling cancer.

Resumo

Public USParticipação acionária
1982Ano de fundação
33Funcionários
New Jersey, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Imunon

  • LEAPS technology platform for vaccine development, focusing on autoimmune diseases and cancer.
  • COVID-19 vaccine candidates, utilizing LEAPS for coronavirus variants.
  • Therapeutic vaccines for Rheumatoid Arthritis, leveraging LEAPS platform.
  • HIV vaccine development program, applying LEAPS technology for prevention.
  • Inflammatory diseases treatment solutions, targeting conditions like Crohn's disease.
  • Collaborations with academic and industry partners for advancing vaccine research and development.

equipe executiva do Imunon

  • Michael H. TardugnoExecutive Chairman
  • Stacy R. LindborgPresident, CEO & Director
  • Douglas V. FallerChief Medical Officer
  • Joshua BlacherInterim CFO, Principal Financial Officer & Principal Accounting Officer
  • Kristin LongobardiSenior Vice President of Strategic Operations
  • Stephen G. MachathaSenior Vice President of Technical Operations

Principais indicadores financeiros

Resultados divulgados pela Imunon, em USD.

Cap. de mercado
21,3 mi
Receita (TTM)
125 mil
P/L
—
LPA (diluído, TTM)
-3.8
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Imunon
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-14,7 mi-14,5 mi
0-19,1 mi-18,6 mi
125 mil-21 mi-19,5 mi
500 mil-24,9 mi-35,9 mi